AI Driven Modeling Target Simulations Plus for expanding AI and ML driven modeling workflows, highlighting opportunities to upgrade or scale physiologically based pharmacokinetics and quantitative systems pharmacology tools as they pursue accelerated regulatory submissions.

GPU Accelerated Leverage NVIDIA collaboration to offer GPU-accelerated AI modeling solutions and scalable cloud compute options to improve turnaround times on complex simulations for drug discovery and development.

Regulatory Readiness Position offerings as enablers for streamlined regulatory submissions, emphasizing robust model validation, traceability, and reporting capabilities that align with FDA and global regulatory expectations.

Strategic Investment Capitalize on potential acquisition interest from Altaris and related private equity activity by presenting flexible licensing and services models, including co-development or integration partnerships to extend market reach.

Earnings Momentum Use recent quarterly earnings improvements to engage growth-focused buyers with case studies on operational efficiency, cost-effective sandbox environments, and ROI from adopting advanced modeling tools.